
Feb 28 (Reuters) - FDA:
FDA ISSUES CLASS-WIDE LABELING CHANGES FOR TESTOSTERONE PRODUCTS
FDA: RECOMMENDING CHANGES TO CURRENT LABELING LANGUAGE TO INCLUDE ADDING RESULTS OF TRAVERSE TRIAL TO ALL TESTOSTERONE PRODUCTS
FDA: RECOMMENDS REMOVING LANGUAGE FROM BOXED WARNING RELATED TO INCREASED RISK OF ADVERSE CARDIOVASCULAR OUTCOMES FOR ALL TESTOSTERONE PRODUCTS
FDA: RECOMMENDS TO ADD WARNING ABOUT INCREASED BLOOD PRESSURE FOR TESTOSTERONE PRODUCTS WHICH DO NOT HAVE SUCH WARNING IN THEIR LABELING